Pharmacodynamics
Serum glucose level at OGTT after EVO+GLI was lower than that after EVO
or GLI (Figure 3). Gmax in the EVO+GLI was lower by
8.0% compared to that in EVO and 6.4% compared to that in GLI. Similar
to Gmax, AUGC in EVO+GLI was also lower by 20.4% and
8.6% compared to that in EVO and GLI, respectively. 2-h PBG showed a
similar pattern to Gmax and AUGC (Table 3). Likewise,
ΔGmax and ΔAUGC in EVO+GLI were lower than those in EVO
or GLI (Table 3).
Serum insulin level after EVO+GLI was higher than that after EVO or GLI
(Figure 3). Emax in EVO+GLI was higher by 98.6%
compared to that in EVO and 18.8% compared to that in GLI. AUEC in
EVO+GLI was also higher by 81.2% and 16.5% compared to those in EVO
and GLI, respectively (Table 3). Likewise, ΔEmax and
ΔAUEC in EVO+GLI were higher than that in EVO or GLI (Table 3).